Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 16/20 | 1.00 |
| ▸ | BCHE known ✓ | P06276 | 8/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CACNB4 | O00305 | 1/20 | 1.00 |
| ▸ | CACNA1A | O00555 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | CACNA1G | O43497 | 1/20 | 1.00 |
| ▸ | CACNG3 | O60359 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | CACNA1H | O95180 | 1/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 1.00 |
| ▸ | FABP1 | P07148 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tacrine SCHEMBL7714835 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL29594645 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL29681895 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL9407893 | 0.98 | CYP1A2 (0.97) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL8000475 | 0.98 | ACHE (0.97) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL7638777 | 0.98 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| SCHEMBL12043403 | 0.98 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL3270 | 0.98 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL14236722 | 0.98 | ACHE (0.97) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL1044163 | 0.98 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 38280 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744680-A1 | TARGETED CHEMICAL DRUG AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE OF TARGETED CHEMICAL DRUG | Bai Yao Zhi Da (Beijing) Nanobio Technology Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| CN-122036607-A | Central targeting type tacrine conjugate based on transporter and preparation method and application thereof | 中国药科大学 | 2026-05-15 | — | — | CN | claimed |
| EP-4429648-B1 | NOVEL SYNERGISTIC COMBINATIONS BASED ON FLUOROETHYLNOREMMANTINE (FENM) AND AN ACETYLCHOLINESTERASE INHIBITOR FOR USE IN THE TREATMENT OF NEURODEGEATIVE DISEASES | REST THERAPEUTICS (FR) | 2026-05-13 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-12584131-B2 | Methods of gene therapy | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2026-03-24 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4683627-A1 | AMELIORATION OF DRUG-DRUG INTERACTIONS | Ontrack Therapeutics Limited (GB) | 2026-01-28 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| US-20250333435-A1 | TIMOSAPONIN COMPOUNDS | GOLDPORP PHARMA LTD (CN) | 2025-10-30 | — | — | US | claimed |
| EP-0375471-A2 | Use of 1,2,3,4-tetrahydro-acridines in the treatment of AIDS, and compounds | STE CIVILE DE RECHERCHE NEWPHARM (FR) | 1990-06-27 | — | — | EP | claimed |
| WO-1990004388-A1 | IN VIVO NEUROTROPHIC CYTOPROTECTIVE ALCOHOLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1990-05-03 | — | — | WO | claimed |
| US-4876260-A | NERVOUS SYSTEM DISORDERS | STATE OF ISRAEL, ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IL) | 1989-10-24 | — | — | US | claimed |
| WO-1989009600-A1 | METHOD AND COMPOSITION FOR TREATING NEUROLOGICAL DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-10-19 | — | — | WO | claimed |
| EP-0332147-A2 | Compositions with enhanced penetration | WARNER-LAMBERT COMPANY (US) | 1989-09-13 | — | — | EP | claimed |
| US-4855290-A | Derivatives of quinuclidine | STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1989-08-08 | — | — | US | claimed |
| EP-0314444-A2 | Novel oxathiolanes and derivatives thereof, pharmaceutical compositions containing them and the use thereof as medicaments | State of IsraelRepresented by the Prime Minister's OfficeThe Israel Institute for Biological Research (IL) | 1989-05-03 | — | — | EP | claimed |
| EP-0303391-A2 | Optical isomers of a spiroquinuclidine derivative | State of IsraelRepresented by the Prime Minister's OfficeThe Israel Institute for Biological Research (IL) | 1989-02-15 | — | — | EP | claimed |
| US-4788063-A | FATTY ACID, CHOLINERGIC OR ANTICHOLINERGIC AGENT | STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1988-11-29 | — | — | US | claimed |
| EP-0205247-A2 | Derivatives of quinuclidine | STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1986-12-17 | — | — | EP | claimed |